Quarterly ResultApr 30, 2026, 04:10 PM
DXCM Q1 Revenue +15% to $1.19B; EPS $0.51; Raises FY26 Margin Guidance
AI Summary
Dexcom reported strong first-quarter 2026 financial results, with revenue increasing 15% year-over-year to $1.192 billion and GAAP diluted EPS rising to $0.51 from $0.27. The company also saw significant improvements in GAAP operating income, which grew 850 basis points to $255.3 million. Strategically, Dexcom expanded the launch of its G7 15 Day CGM in the U.S. and introduced new features to its Stelo platform. Following this performance, Dexcom raised its fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, while reiterating revenue and gross profit margin guidance.
Key Highlights
- Q1 2026 Revenue grew 15% year-over-year to $1.192 billion (12% organic).
- Q1 2026 GAAP diluted EPS was $0.51, up from $0.27 in Q1 2025.
- Q1 2026 GAAP operating income increased 850 basis points to $255.3 million (21.4% of revenue).
- U.S. revenue grew 11% and international revenue grew 26% (17% organic) year-over-year.
- Raised FY26 Non-GAAP Operating Margin guidance to 23-23.5% and Adjusted EBITDA Margin to 31-31.5%.
- Reiterated FY26 Revenue guidance of $5.16 - $5.25 billion (11-13% growth).
- Expanded launch of Dexcom G7 15 Day CGM across all channels in the United States.
- Held $2.42 billion in cash, cash equivalents, and marketable securities as of March 31, 2026.